Dogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest Down 40.0% in May

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 65,085 shares, a decline of 40.0% from the May 14th total of 108,418 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average trading volume of 44,667 shares, the days-to-cover ratio is presently 1.5 days.

Hedge Funds Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP bought a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. Institutional investors own 9.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DWTX. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a research note on Tuesday, May 19th. Weiss Ratings cut shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Trading Up 1.9%

NASDAQ:DWTX traded up $0.03 during trading hours on Monday, hitting $1.57. 70,684 shares of the company traded hands, compared to its average volume of 77,052. The stock has a market capitalization of $52.80 million, a price-to-earnings ratio of -0.15 and a beta of 1.70. Dogwood Therapeutics has a twelve month low of $1.28 and a twelve month high of $9.50. The firm has a 50-day moving average of $1.69 and a 200 day moving average of $3.03.

Dogwood Therapeutics (NASDAQ:DWTX) last released its earnings results on Thursday, May 14th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. Equities research analysts predict that Dogwood Therapeutics will post -0.55 earnings per share for the current fiscal year.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.